ReviewAnnals of internal medicine2020
Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review.
Review in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Coronavirus disease 2019, vaccination against coronavirus and immunoglobulin A-mediated diseases: systematic literature review.Journal of autoimmunity · 2022Pooled it
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022Pooled it
- Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Pooled it
- Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2021Pooled it
- Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2020Pooled it
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2020Pooled it
- COVID-19 serology in nephrology healthcare workers.Wiener klinische Wochenschrift · 2021Trial
- Seroprevalence of SARS-CoV-2 in Tanzania: results from a cross-sectional study documenting the Omicron wave in five regions of Tanzania.BMC public health · 2026Article
- Article
- Seroprevalence of Immunoglobulin M and G antibodies to severe acute respiratory syndrome coronavirus 2 infection in Iwo, Nigeria.BMC infectious diseases · 2025Article
- COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.Epidemiologia (Basel, Switzerland) · 2025Article
- Article
- Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence.Heliyon · 2024Article
- Incomplete Kawasaki disease with muscular weakness and bladder retention: a case report.BMC pediatrics · 2024Article
- SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies.Biomolecules & biomedicine · 2024Review
- Evaluation of a New Standardized Nasal Sampling Method for Detection of SARS-CoV-2 RNA via RT-PCR.Microorganisms · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. Many use cases are envisaged, including complementing molecular methods for diagnosis of active disease and estimating immunity for individuals. At the population level, carefully designed seroepidemiologic studies will aid in the characterization of transmission dynamics and refinement of disease burden estimates and will provide insight into the kinetics of humoral immunity. Yet, despite an explosion in the number and availability of serologic assays to test for antibodies against SARS-CoV-2, most have undergone minimal external validation to date. This hinders assay selection and implementation, as well as interpretation of study results. In addition, critical knowledge gaps remain regarding serologic correlates of protection from infection or disease, and the degree to which these assays cross-react with antibodies against related coronaviruses. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.